Limited coverage drugs – filgrastim

Brand name

Strength

Form

Grastofil^®

300 mcg/0.5 mL 
480 mcg/0.8 mL

pre-filled syringe

Nivestym^®

300 mcg/0.5 mL 
480 mcg/0.8 mL

pre-filled syringe

300 mcg/1 mL
480 mcg/1.6 mL

single-use vial

Nypozi™

300 mcg/0.5 mL
480 mcg/0.8 mL

pre-filled syringe

For primary prophylaxis of febrile neutropenia in cancer patients receiving potentially curative myelosuppressive chemotherapy regimens where the risk of febrile neutropenia is ≥ 20%

6 months

For secondary prophylaxis of febrile neutropenia in cancer patients receiving potentially curative myelosuppressive chemotherapy

6 months

For the rescue of prolonged febrile neutropenia following chemotherapy

6 months

For cancer patients undergoing peripheral blood progenitor cell collection and therapy

6 months

For post-bone-marrow transplant patients to stimulate bone marrow engraftment (start greater than or equal to d+1)

6 months

For post-bone-marrow transplant patients requiring rescue of failure to engraft (start greater than or equal to d+14)

6 months

For patients with the following benign disorders:

• chronic benign cyclical neutropenia
  OR
• myelodysplastic disorders or aplastic anemia, while the patient awaits bone marrow transplantation

6 months